December 2025, Vol 6, No 4

Welcome to the final edition of CCA News for this season. This end-of-season issue reflects highlights from the 2025 Cholangiocarcinoma (CCA) Summit held in Scottsdale, AZ, where international experts presented leading advances in CCA.

Experts explored the use of targeted therapies in frontline treatment of biliary tract cancer, emphasizing their efficacy in biomarker-defined groups, trial enrollment challenges, and the need for stronger clinical evidence.

Dr Nadim Ajami explored the transformative role of microbiome research in advancing the care of patients with cancer and improving patient outcomes.

Artificial intelligence is revolutionizing biliary tract cancer care with breakthroughs in radiomics, precision diagnostics, and personalized treatment insights.

Combining immune checkpoint inhibitors with surgery, targeted therapies, and antibody–drug conjugates is emerging as a powerful strategy to improve outcomes in biliary tract cancers.

Advancing clinical trials in biliary tract cancer hinges on precision medicine, biomarker-driven strategies, and global collaboration to close evidence gaps and improve patient outcomes.

Breakthrough treatment strategies and surgical approaches are redefining survival for patients with high-risk cholangiocarcinoma.

Experts highlighted how multidisciplinary care drives enhanced outcomes for patients with cholangiocarcinoma.

As a novel treatment modality, experts debate on histotripsy’s potential as a groundbreaking ultrasound therapy for liver and biliary tract cancers.

The Cholangiocarcinoma Foundation (CCF) is pleased to announce a series of upcoming regional symposia designed to bring together patients, caregivers, clinicians, researchers, and advocates from across the country.